Syngene International Limited Q3 and 9 Month FY 2024 Results Conference Call Points :
-
Now for the quarter, we delivered 9% revenue growth in the course from operations
-
Slowdown in the U.S. biotech funding did impact Discovery Services
-
We expect a little bit slower growth coming out of the U.S. biotech segment for 1, 2, maybe 3
more quarters before it annualizes out
Subscribe To Our Free Newsletter |